Market Overview - The A-share market exhibited a fluctuating upward trend this week, with major broad-based indices showing mixed performance and significant market style differentiation [1] - International gold prices recently reached a new historical high, leading to strong performance in related ETFs, with gold stock ETFs rising by 13.17%, the highest among all [1][2] - Other sectors such as photovoltaic and building materials ETFs also saw substantial gains, while Hong Kong innovative drug-related ETFs experienced slight adjustments [1] Fund Flow Analysis - Overall, ETF funds experienced a net outflow of 696.39 billion, with broad-based ETFs facing a net outflow of 873.01 billion, while industry ETFs saw a net inflow of 143.04 billion and commodity ETFs a net inflow of 32.91 billion [3] - Funds have not exited the market but have shifted towards more elastic sectors, with significant net inflows into TMT (Technology, Media, Telecommunications) and cyclical sectors like non-ferrous metals, indicating active funds' preference for technology growth themes [2][3] ETF Performance - The top-performing gold stock ETFs included: - 517400 Gold Stock ETF with a 13.17% increase and a latest scale of 826 million [2] - 159315 Gold Stock ETF from ICBC with a 13.03% increase and a scale of 222 million [2] - 517520 Gold Stock ETF from Yongying with a 12.95% increase and a scale of 177.52 billion [2] - Photovoltaic ETFs also performed well, with the top performer being 560980 Photovoltaic Leader ETF from GF with a 10.71% increase and a scale of 565 million [2] Upcoming ETF Listings - Next week, four new ETFs are set to be listed, including: - 589190 Sci-Tech Chip ETF from Huabao, with subscription starting on December 30, 2025 [5] - 159158 Power ETF from Invesco, with subscription starting on January 7, 2026 [5] - 589220 Sci-Tech 200 ETF from Guotai, with subscription starting on January 5, 2026 [5]

港股创新药概念股走低，翰森制药跌超4%，信达生物、中国生物制药、三生制药、科伦博泰生物-B跌超3%。 受盘面影响，多只港股创新药相关ETF跌超2%。 | 代码 名称 现价 | 类型 | | 涨跌 涨跌幅 ▲ | | --- | --- | --- | --- | | 520850 跨 N港股通医疗ETF易方达 | | 0.978 | -0.025 -2.49% | | 159570 跨 港股通创新药ETF T+0 | | 1.690 | -0.038 -2.20% | | 520700 跨 港股创新药ETF基金 T+0 | | 1.652 | -0.035 -2.07% | | 513780 跨 港股创新药50ETF T+0 | | 1.713 | -0.036 -2.06% | | 520970 跨 港股通创新药ETF嘉实 T+0 0.924 | | | -0.019 -2.01% | 有券商表示，创新药核心资产仍将上行，小核酸、体内CAR新机遇层出不穷。创新药BD是长期产业趋势，是中国创新药力量进入世界舞 台的价值兑现，对于已授权MNC的核心资产将随着临床进展持续兑现价值。除此以外，未来仍要锚定前沿技术平 ...

Group 1 - The core viewpoint is that Hong Kong's innovative pharmaceutical stocks are experiencing a strong upward trend, with notable increases in companies such as Kangfang Biotech (over 6%), Innovent Biologics (over 5%), and Zai Lab (over 4%) [1] - Several Hong Kong innovative pharmaceutical-related ETFs have also risen nearly 3% due to market influences [1] - The analysis indicates that the overseas easing cycle typically benefits biotech assets, with the Nasdaq Biotechnology Index rising by 13% since the interest rate cut on September 18, 2025, suggesting an improved financing environment that may enhance the operational vitality of biotech companies [2] Group 2 - Recent positive developments in China's biotechnology sector include multiple innovative pharmaceutical companies having 35 studies selected for oral presentations at the ESMO 2025 conference, setting a new record [3] - Significant benchmark business development collaborations are emerging, such as the partnership between Innovent Biologics and Takeda, which has a total scale of up to $11.4 billion, reflecting global market recognition of the value of Chinese innovative drugs [3]

Group 1 - Hong Kong pharmaceutical stocks weakened, with Innovent Biologics down over 4%, China Biologic Products down over 3%, and other companies like CanSino Biologics, CSPC Pharmaceutical Group, and Kelun-Biotech down over 2% [1] - The Hong Kong innovative drug-related ETFs also fell by over 2% due to market influences [1] Group 2 - Various Hong Kong innovative drug ETFs experienced declines, with the Southbound T+0 ETF down 3.52%, the Hang Seng Innovative Drug ETF down 2.92%, and others showing similar downward trends [2] - Analysts suggest that after a decade of transformation, China's innovative drug industry is entering a harvest period, with a steady increase in the number of domestically approved innovative drugs and significant overseas transactions [2]

Group 1 - The A-share market showed a fluctuating upward trend from September 8 to September 12, with chip and semiconductor-related ETFs leading the gains, with two chip-related ETFs rising over 10% [1] - A total of 1,095 ETFs achieved positive returns during the same period, with over 80% of products showing positive returns, particularly in the chip and semiconductor sectors [1][2] - The overall net inflow of funds into the ETF market was 6.946 billion yuan, with stock-type ETFs being the main contributors to this inflow [2][3] Group 2 - Battery-related ETFs also performed well, with the lithium battery ETF rising by 17.74% since the beginning of September, while six gold stock-related ETFs saw an increase of around 14% [2] - The highest trading volumes were recorded for ETFs tracking the CSI A500, Hang Seng Technology, and Hong Kong Securities Index, with weekly trading volumes reaching 126.76 billion yuan, 91.54 billion yuan, and 79.88 billion yuan respectively [3] - The net outflow of funds was primarily seen in sci-tech related ETFs, with the Sci-Tech 50 ETF experiencing a net outflow of 4.161 billion yuan [3] Group 3 - The outlook for the A-share market remains positive, supported by loose liquidity and potential interest rate cuts from the Federal Reserve, which may lead to a revaluation of global risk assets [3][4] - The market is expected to attract more external funds due to favorable domestic policies and a continued focus on capital returns [4] - Investment opportunities are suggested in the AI industry chain and advanced manufacturing sectors, which are expected to improve fundamentally [4]

Core Viewpoint - The innovative pharmaceutical sector in Hong Kong experienced significant fluctuations, with major companies like CSPC Pharmaceutical and Hansoh Pharmaceutical seeing declines of over 8%, while BeiGene dropped more than 6% [1] Group 1: Market Performance - Multiple Hong Kong innovative pharmaceutical ETFs fell by over 3% due to market influences [1] - Specific ETFs reported declines, such as the Hang Seng Innovative Pharmaceutical ETF down 4.41% and the Hong Kong Innovative Pharmaceutical ETF down 4.06% [2] Group 2: Future Outlook - Some brokerages suggest that the long-term bullish trend for innovative pharmaceuticals may not be over, as the commercialization value of innovative drug assets driven by Chinese engineers has yet to be fully realized [2] - The valuation of the Hong Kong innovative pharmaceutical sector is considered low, with a high certainty of business development (BD) landing numbers, indicating potential for future growth in areas like small nucleic acids and oral GLP-1 [2] - The ongoing high bidding and acquisition amounts in the sector reflect its explosive potential [2]

Market Overview - Major A-share indices collectively rose, with the Shanghai Composite Index reaching a ten-year high, closing up 1.04% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2,408.2 billion [1] ETF Performance - The top-performing ETFs were related to the semiconductor sector, with the Sci-Tech Chip Design ETF (588780) leading with a 5.57% increase [2] - Other notable gainers included various Sci-Tech Chip ETFs, all showing significant increases ranging from 4.65% to 4.97% [2] Semiconductor Industry Insights - Nvidia is developing a new AI chip for China, named B30A, which will outperform the currently allowed H20 model [3] - The global semiconductor market is expected to continue its optimistic growth trajectory, driven by AI and domestic substitution trends [3] Declining ETFs - The Hong Kong innovative drug-related ETFs experienced declines, with the Hang Seng Medical ETF falling by 3.82% [4] - Other ETFs in the innovative drug sector also reported losses, indicating a challenging environment for this segment [4] Trading Activity - The Short-term Bond ETF (511360) had the highest trading volume at 23.661 billion [5] - The turnover rate was led by the Benchmark Treasury ETF (511100) at 165.78%, indicating high trading activity [6] New ETF Launches - Two new ETFs are set to launch, focusing on the general aviation industry and the core assets of the ChiNext board, enhancing the diversity of investment options available [7]

Group 1 - The core viewpoint indicates a decline in Hong Kong's innovative pharmaceutical stocks, with notable drops in companies such as CSPC Pharmaceutical, which fell over 8%, and Innovent Biologics, which dropped over 5% [1] - Multiple Hong Kong innovative pharmaceutical ETFs also experienced declines, with losses exceeding 3% [1] Group 2 - Specific ETF performance shows that the Hong Kong Innovative Drug ETF (code: 513120) decreased by 3.93%, closing at 1.418, while the Hong Kong Innovative Drug 50 ETF (code: 513780) fell by 3.81%, closing at 1.819 [2] - Analysts believe that domestic medical insurance policy support and overseas value recognition will sustain the ongoing trend of Chinese innovative pharmaceuticals, with China projected to become a core procurement area by 2025 [2] - The pressure from multinational corporations facing "patent cliffs" necessitates the search for quality assets, and China's high R&D cost-effectiveness and increasing overseas recognition are driving the trend of innovation going global [2]

Core Viewpoint - The pharmaceutical sector has shown significant divergence in performance, with innovative drugs outperforming while other segments like medical devices and traditional Chinese medicine lag behind [1][2][3] Group 1: Performance Disparity - As of July 28, the performance gap among pharmaceutical theme funds exceeded 120%, with funds focused on Hong Kong innovative drugs leading the pack [1][2] - The China Securities Index for Hong Kong innovative drugs recorded a year-to-date increase of 111.08%, while the medical index only rose by 14.74% [2][3] - A total of 393 pharmaceutical-related funds were tracked, with the highest fund showing a net value increase of over 120% and the lowest at -3.08% [3] Group 2: Market Trends - The A-share pharmaceutical stocks continued to rise, with CRO concept stocks leading the gains, and multiple stocks increasing over 5% [2] - Hong Kong's biotechnology and healthcare indices also performed well, with increases of 4.11% and 3.82% respectively [2] - Despite the overall strong performance, there is a clear divide between the booming innovative drug sector and the underperforming medical and traditional Chinese medicine sectors [2][3] Group 3: Investment Strategies - Some fund managers have reduced their holdings in high-performing sectors like innovative drugs, opting for a balanced approach across medical devices and consumer healthcare [4] - The focus on defensive positions and dividend stocks has been noted as a reason for underperformance in certain funds [3][4] - Analysts suggest that while innovative drugs are currently strong, there are opportunities for valuation recovery in medical devices and healthcare sectors [6][7] Group 4: Risks and Future Outlook - The innovative drug sector's recent surge is attributed to favorable policies, successful international business development, and improved fundamentals [6] - However, there are accumulating short-term risks, including high trading congestion and potential regulatory hurdles [6] - Analysts from CITIC Construction Investment predict a recovery in the medical device sector's overall valuation, with several companies expected to turn profitable by 2025-2027 [7]

Market Performance - The A-share market continued its strong upward trend, with the Shanghai Composite Index approaching the 3500-point mark, closing at 3472.32 points, reflecting a weekly increase of 1.4% [1] - Over 70% of ETF products achieved positive returns this week, with the Hong Kong innovative drug-related ETFs leading the gains [1][2] ETF Highlights - After a two-week adjustment, Hong Kong innovative drug-related ETFs surged again, with several products, including the Hong Kong Innovative Drug ETF Fund and the Hong Kong Innovative Drug 50 ETF, seeing weekly increases exceeding 7% [5][6] - The median weekly increase for over 1200 ETF products was 1.08%, with only about 200 products experiencing declines [2] - Notably, the steel ETF (515210) saw a significant rise of 5.41%, attributed to Huazhong Steel being targeted by insurance capital [6] Sector Performance - Game-related ETFs also performed well, with several products recording weekly gains of over 6%, driven by substantial increases in constituent stocks such as Kaineng Network and 37 Interactive Entertainment [6] - Conversely, the Hang Seng Technology Index faced a decline of 2.42%, impacting related products, particularly in the internet sector, which saw declines exceeding 3% for several ETFs [8][9] Notable ETF Data - The top-performing Hong Kong innovative drug ETFs included: - Hong Kong Innovative Drug ETF Fund: 7.553% weekly increase - Hong Kong Innovative Drug 50 ETF: 7.483% weekly increase - Hong Kong Innovative Drug ETF ICBC: 7.477% weekly increase [4][5] - The newly established Huabao Hang Seng Hong Kong Innovative Drug Selected ETF (520880) reported that Barclays Bank holds 20 million shares, accounting for 4.5997% of the total fund [6]